• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    4.845 -0.355 (-6.83%)
    Streaming Delayed Price Updated: 3:56 PM EDT, Mar 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Iovance Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    22 23 Next >
    News headline image
    Top stock movements in today's session. ↗
    Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Gapping stocks in Thursday's session ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    Why Are IOVA Shares Rising Today? ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
     
    Via Benzinga
    Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
    Via Stocktwits
    News headline image
    Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
     
    Via Benzinga
    News headline image
    Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    Via Investor Brand Network
    News headline image
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
    October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
    Via MarketMinute
    Topics Intellectual Property Workforce
    News headline image
    Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health ↗
    Is there a glimmer of hope for either of these underperforming healthcare companies? 
    Via The Motley Fool
    News headline image
    Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? ↗
    Investors have certainly seen explosive gains from shares of biopharma companies in similar situations. 
    Via The Motley Fool
    News headline image
    IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Can This Beaten-Down Stock Bounce Back? ↗
    This biotech company is innovative, but the market demands more than that. 
    Via The Motley Fool
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today ↗
    The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
    Via The Motley Fool
    News headline image
    Why Iovance Biotherapeutics Stock Got Mashed on Monday ↗
    The company announced a flotation of its common shares that is potentially quite dilutive. 
    Via The Motley Fool
    News headline image
    Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
     
    Via Benzinga
    News headline image
    1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street ↗
    Time is running out for the company to mount a comeback. 
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Iovance Biotherapeutics Stock Was Climbing Today ↗
    One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    22 23 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.